BERG, The Icahn School of Medicine at Mount Sinai to host "Fast Track" event at Fast Company's Second Annual Innovation Festival 2016

BOSTON, Oct. 31, 2016 /PRNewswire/ -- BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, and the Icahn School of Medicine at Mount Sinai will host a "Fast Track" event at Fast Company's Innovation Festival 2016. The event will take place on Wednesday, November 2, 2016 from 9:30AM – 11:00AM at The Hess Center for Science and Medicine at Mount Sinai.

The event, titled "How BERG and Mount Sinai Are Innovating to Fulfill the Promise of Precision Medicine," will welcome healthcare leaders to discuss how artificial intelligence, big-data analytics, and genomics accelerate drug discovery to deliver treatments to patients faster.

The panel will feature a broad range of precision medicine leaders to discuss innovations from biopharma companies like BERG and new research initiatives from leading academic medical institutions that are delivering on the promise of "precision medicine" to identify the right drug, for the right patient, at the right time. Esteemed panel speakers include:

• Andrea Califano, PhD, Professor of Chemical Biology and Systems Biology; Chair of Systems Biology at Columbia University
• Sam Gandy, MD, PhD, Mount Sinai Professor of Alzheimer's Disease Research; Professor of Neurology and Psychiatry, Director of the Center for Cognitive Health at Mount Sinai
• Niven R. Narain, Co-founder, President and CEO of BERG
• Eric Nestler, MD, PhD, Nash Family Professor of Neuroscience and Director of the Friedman Brain Institute at Mount Sinai
• Eric Schadt, PhD, Professor & Chair, Genetics and Genomic Sciences; Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai

"Fast Tracks," which are a key program element of Fast Company's Second Annual Innovation Festival 2016, are a rare opportunity to go behind the scenes at New York City's most inspiring organizations. Each visit will be hosted by company leaders at the offices, studios, and work spaces where their ideas come to life.

"At BERG, we were founded on the premise that we need to treat the patient, not the disease," said Niven R. Narain, Co-founder, President and CEO of BERG. "We are excited to share a behind-the-scenes look at the next generation of medicine and healthcare made possible by emerging technologies."

"Healthcare today is a new frontier where patients, more than ever, are playing an integral role in determining and developing their individual treatment," said Eric Nestler, MD, PhD, Nash Family Professor of Neuroscience and Director of the Friedman Brain Institute at Mount Sinai. "We are in the midst of a shift in the way we treat disease, and Mount Sinai is excited to welcome Fast Company Innovation Festival attendees for a preview of the future of modern healthcare."

The Fast Company Innovation Festival will be held November 1-4, 2016 in New York City. To purchase tickets and to see complete festival information, go to fastcompany.swoogo.com/innovationfestival

About BERG
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles, demographics and biology.  BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic product candidates and develop companion diagnostics to enhance specificity in its drug development process. 

BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology. Its lead drug, BPM-31510 (IV), has the potential to slow or reverse cancer cell growth by changing a hypothesized fundamental driver of many different types of cancer.  BERG has initiated a Phase II clinical trial for BPM-31510 (IV) in advanced pancreatic cancer in combination with a common cancer drug, among other ongoing and planned trials for BPM-31510 (IV) in various oncological indications.

For additional information, please visit www.BERGhealth.com.

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the "Honor Roll" of best hospitals in America, ranked No. 15 nationally in the 2016-2017 "Best Hospitals" issue of U.S. News & World Report.  The Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai's Kravis Children's Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in "Best Children's Hospitals."

For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.

SOURCE BERG

Related Links

http://www.BERGhealth.com